Chemed Corporation 2008 Form 10-K Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2008. Chemed Corporation operates through two primary segments: Vitas Group, the nation's largest provider of hospice services, and the Roto-Rooter Group, a provider of sewer, drain, and pipe cleaning services. The company is a large accelerated filer incorporated in Delaware. As of February 16, 2009, there were 22,530,217 shares of capital stock outstanding.
Key Financial Metrics
Note: Specific revenue, net income, and cash flow figures for 2008 are incorporated by reference from the 2008 Annual Report to Stockholders and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Debt Reduction: The company reduced outstanding debt by $15 million in 2008.
- Variable Rate Debt: As of December 31, 2008, the company had $22.7 million of variable rate debt outstanding.
- Long-Term Debt: The carrying value of long-term debt was approximately $209.8 million, with a market value of approximately $147.2 million.
- Interest Rate Sensitivity: For every $10 million of variable debt, a 100 basis point change in interest rates alters annual interest expense by $100,000.
- Stock Performance: The cumulative total stockholder return for the five-year period ending December 31, 2008, was 177.78 (base 100 in 2003), compared to 88.67 for the S&P 500.
- Dividends: The company paid a quarterly dividend of $0.06 per share throughout 2008.
- Share Repurchases: Under the April 2007 program, the company repurchased shares in Q1, Q2, and Q3 of 2008. By year-end, $53.9 million remained available under the program.
- Allowance for Doubtful Accounts: The balance at the end of 2008 was $10.32 million.
Material Changes and Operational Highlights
- Seasonality: Roto-Rooter results are impacted by fourth-quarter advertising costs. In Q4 2008, the segment expensed $7.4 million in advertising, representing 31% of its full-year costs.
- Employee Count: Total employees were 11,884 as of December 31, 2008.
- Environmental Liabilities: The accrual for potential environmental cleanup costs related to the former DuBois Chemicals Inc. was $1.7 million. The company is contingently liable for up to an additional $14.9 million, though management does not believe payment is probable.
- Medicare Cap Liability: As of December 31, 2008, no cap liability was recorded for 2008. A liability of $235,000 was recorded for one program for the 2009 measurement period.
Guidance, Risks, and Contingencies
Regulatory and Reimbursement Risks: Over 90% of Vitas revenue comes from Medicare and Medicaid. Profitability is highly sensitive to reimbursement rates, which are adjusted annually but may lag inflation. The company faces risks related to the "80-20" rule for inpatient care and overall hospice payment caps.
Legal Proceedings:
- Costa Settlement: A class action lawsuit regarding wage and hour violations in California was settled for $19.9 million (approved June 2006).
- Santos Lawsuit: A similar class action filed in September 2006 is ongoing; potential liability is currently unestimable.
- OIG Investigation: The Office of Inspector General (OIG) continues to investigate allegations regarding billing practices. A related qui tam complaint was dismissed with prejudice in 2007, but the government investigation remains open.
Debt Covenants: The company's debt instruments contain restrictive covenants limiting additional debt, dividends, asset sales, and capital expenditures. A default could accelerate repayment obligations.
Investor Verification Checklist
- Verify the specific Revenue and Net Income figures for 2008 in the Consolidated Statement of Income (incorporated by reference), as these are not explicitly stated in the text provided.
- Review the 2008 Annual Report to Stockholders for the detailed segment data (Vitas vs. Roto-Rooter) referenced in Note 4.
- Monitor the status of the OIG investigation and the Santos class action lawsuit for potential future liabilities.
- Assess the impact of Medicare/Medicaid reimbursement rate changes on Vitas margins, given the 90% revenue dependency.
- Confirm the company's ability to service its $209.8 million debt load, particularly given the variable rate exposure of $22.7 million.